Changes in Hong Kong stocks | Danno Pharmaceutical-B (06872) rose more than 7% intraday, TNP-2092 prioritizes the development of intra-articular injections to treat artificial joint infections

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Danuo Pharmaceutical-B (06872) rose more than 7% in the intraday period. As of press release, it had risen 7.66% to HK$70.7, with a turnover of HK$6.325 million.

According to the news, on October 30, Danno Pharmaceutical-B issued an announcement. After comprehensive consideration of existing clinical data, unmet clinical needs, competitive landscape and commercial potential of the new drug candidate rifoquinone (TNP-2092), the company has selected the treatment of artificial joint infections (PJI) through intra-articular injection as the core priority development indication for rifuziquantel.

As the Group's core pipeline, rifuquinone has many application prospects. The phase IIa proof-of-concept clinical trial of rifuquinone was administered through intra-articular injection to treat PJI. The first patient was enrolled in the multi-center phase IIb clinical trial. The trial aims to further evaluate the efficacy, safety, and pharmacokinetic characteristics of rifaquinone in treating PJI without debridement or revision surgery, and marks a critical stage in clinical development of this potentially disruptive new drug product.